Next-Generation Sequencing

High-throughput 3’ RNA-seq

Advances in cell signaling research using 3' RNA-seq

Unraveling the complexity of cell signaling pathways can advance the understanding of various diseases. The use of 3’ RNA sequencing has been instrumental in this field, creating a need for high-throughput solutions that afford increased accuracy, specificity and sensitivity. QIAGEN's QIAseq UPX 3' Transcriptome Kit, also available as a service, addresses these requirements by providing high-throughput 3' transcriptome NGS from ultralow amounts of RNA.

Discover through inspirational stories below how QIAseq UPX 3' Transcriptome technology facilitated a deeper understanding of diabetes through gene expression and cell signaling analysis and interpretation.

Simona Chera, Ph.D., Associate Professor, University of Bergen
Encapsulation boosts islet-cell signature in differentiating human hiPSCs via integrin signalling
“For us, the QIAseq UPX 3’ Transcriptome approach was a life-saver, allowing high-throughput sequencing on ultralow amounts of RNA isolated from hard-to-process samples. The results obtained exceeded our expectations. This is an approach to keep in mind when RNA quantity is below the minimal threshold.”

Discover how Dr. Simona Chera and her team at the Department of Clinical Science, University of Bergen, successfully used QIAseq UPX 3' Transcriptome Kits, GeneGlobe and QIAGEN Digital Insights to investigate the development of human-induced pluripotent stem cells (hiPSCs) into insulin-producing pancreatic islet cells for potential use in diabetes treatment.

Uncovering the connection between arsenic and type II diabetes
"QIAGEN's UPX 3’ Transcriptome service allowed us to generate a large-scale RNA-seq data set that facilitated our discovery of key gene expression changes that drive our disease model."

Have a look at the exciting new research by Dr. Matthew Dodson and Dr. Donna Zhang from the University of Arizona, who investigated the role of Nrf2 regulation in diabetic disease.

[Webinar] Uncovering the connection between arsenic and type II diabetes
Matthew Dodson, Ph.D., Post-Doctoral Researcher, University of Arizona

On-demand webinar – watch now

Investigating the Nrf2 transcriptome as a driver of arsenic-promoted type II diabetes

Speakers: Matthew Dodson, Ph.D., Department of Pharmacology and Toxicology, University of Arizona and Raphael Werding, M.Sc., Genomic Services, QIAGEN

Get started with QIAseq UPX 3’ technology

Boost your gene expression and pathway research – request your QIAseq UPX 3' Transcriptome Trial Kit or reach out to QIAGEN Genomic Services to discuss your project.

All photos taken prior to COVID-19